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ABSTRACT
Purpose: A sentinel lymph node (SLN) tracer can gain multi-functionality by 
combining it with additional components. We developed a SLN tracer consisting of 
iodine and docetaxel and applied it as a theragnostic nanoparticle to simultaneously 
perform SLN computed tomography (CT) lymphography and locoregional 
chemotherapy of the draining lymphatic system.
Results: Docetaxel could be loaded in iodine emulsions at a drug-to-surfactant 
weight ratio as high as that in the drug formulation Taxotere®. The particle size 
and drug concentration were stable during storage for up to 3 months in optimized 
nanoemulsions. Popliteal LN enhancement on CT was observed in all healthy rabbits 
(n=3) and VX2 tumor-implanted rabbits (n=6) 12 hours after injection. The rate of 
SLN metastasis was significantly lower in the treatment group (29.4%, 5/17) than 
in the non-treatment group (70.6%, 12/17) (P=0.038).
Material and Methods: We prepared a nanoemulsion carrying both iodine 
and docetaxel in a single structure by optimizing the composition of surfactants 
surrounding the inner iodized oil core. CT was performed 12 hours after subcutaneous 
injection of the emulsion in healthy rabbits (n=3) and VX2 tumor-implanted rabbits 
(n=6) for SLN imaging. Next, we tested the effect of treatment by histopathologically 
assessing the popliteal LN metastasis rate in VX2 tumor-implanted rabbits 7 days after 
subcutaneous injection of the emulsion (treatment group, n=17) and comparing it 
with that of non-treatment group rabbits (n=17).
Conclusions: We developed an iodine-docetaxel emulsion and demonstrated that 
it can be applied to simultaneously achieve CT SLN imaging and local chemotherapy 
against nodal metastasis.
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INTRODUCTION
Regional lymph nodes (LNs) are one of the most 
frequent sites of early carcinoma metastasis. The presence 
of regional LN metastasis not only reflects a more 
malignant nature of the tumor, but also is a potential source 
of subsequent distant metastasis [1]. It has been reported 
that improved local therapies can lead to better treatment 
outcomes in breast cancer, gastric cancer, rectal cancer, and 
malignancies arising in other organs [1–4]. However, as non-
surgical or minimally invasive treatments are increasingly 
performed, the diagnosis and treatment of regional LN 
metastasis becomes extremely challenging because these 
procedures often omit LN dissection. Therefore, strategies 
to effectively diagnose and eradicate nodal metastatic tumor 
cells are extremely important, especially if a non-surgical 
and/or minimally invasive treatment option is considered.
The sentinel lymph node (SLN) is defined as the 
first LN that directly receives lymph flow from the primary 
tumor, and is the most likely site of early nodal metastasis. 
If the SLN is free from metastasis, the risk of metastasis to 
other LNs is considered low [5]. Therefore, SLN biopsy 
has been established as an effective method to determine 
whether surgical LN dissection is necessary, especially 
in breast cancer and malignant melanoma, and to a lesser 
extent in other kinds of tumors [6–8].
In practice, the basic strategy to identify the SLN 
is to perform peri-tumoral injection of lymphatic tracers 
and subsequently detect the LNs that uptake the tracers. 
Traditionally, radioactive colloids and vital dyes have 
been the most popular lymphatic tracers used. However, in 
spite of their usefulness, these tracers also have technical 
limitations, such as rapid wash away of vital dyes and 
poor resolution for radioactive colloids [9]. To enhance the 
feasibility and expand the applicability of SLN detection, 
several groups, including ours, have recently produced 
and tested various SLN tracers based on various imaging 
modalities, including but not limited to CT [9–11], MRI 
[12, 13], contrast-enhanced ultrasonography [14], and 
optical imaging [9, 15].
In our previous work, we synthesized an emulsion 
consisting of iodine and indocyanine green that served as a 
SLN tracer that enabled hybrid imaging by CT and optical 
imaging [9]. Such experience led us to hypothesize that 
multiple components with different roles can be packaged 
into a single SLN tracer to achieve multi-functionality. We 
speculated that the scope of SLN tracer use may be expanded 
beyond diagnosis to treatment of nodal metastasis if we 
produced a theragnostic emulsion by marinating a cytotoxic 
agent into the scaffold of the SLN tracer. With this approach, 
SLN imaging based on such a tracer would accomplish not 
only SLN detection, but also chemotherapy that selectively 
targets the draining lymphatic system, which might carry 
metastatic tumor cells.
The purpose of this study was to synthesize 
a theragnostic emulsion containing both iodine and 
docetaxel and apply it to a rabbit tumor model, to achieve 
simultaneous SLN detection by CT lymphography and 
locoregional chemotherapy against microscopic metastasis 
within the draining lymphatic system.
RESULTS
Physicochemical characterization of the  iodine-
docetaxel emulsion
The optimal combination of surfactants with a high 
and low hydrophilic-lipophilic balance value is critical for 
achieving a stable and fine emulsion [16]. To produce an 
oil-in-water type emulsion with nanoscale particles, Tween 
80 and Span 85 were selected as the major hydrophilic 
surfactant and lipophilic cosurfactant, respectively. Tween 
80 was also selected because it is the major surfactant used 
in Taxotere®, a commercially available docetaxel product.
We first prepared nanoemulsions of different 
surfactant compositions with a fixed total amount 
of surfactant (240 μmole) to investigate the optimal 
hydrophilic/hydrophobic surfactant ratio in terms of 
the loaded docetaxel concentration and particle size 
of the resultant emulsions. When nanoemulsions were 
prepared with increasing Tween 80 content (25 to 87 
mol%), the loaded docetaxel content increased, but the 
mean particle size of the emulsions decreased in a Tween 
80 content-dependent manner (Supplementary Table I). 
The polydispersity index (PI) of all emulsions was below 
0.3, showing a homogenous distribution of emulsions 
regardless of surfactant composition. Emulsions with 
a >5 mg/ml loaded docetaxel concentration and <100 
nm mean particle size could be obtained with 240 μmole 
total surfactant composed of an 87:13 Tween 80:Span 85 
mixture; we adopted this composition for the synthesis of 
iodine-docetaxel emulsions for further experiments. In case 
of Tween 80:Span 85 micelles (without an oil core), the 
concentration of loaded docetaxel and the mean particle size 
were similar to those of Tween 80:Span 85 emulsions. These 
data indicate that, although docetaxel is somewhat soluble in 
Lipiodol (data not shown), the presence of Lipiodol did not 
further increase docetaxel loading.
Reducing the total surfactant amount may be 
beneficial for reducing surfactant-related side effects, 
such as hypersensitivity reactions after administration 
in cancer patients. We therefore investigated the effect 
of the total amount of surfactant mixture on the loaded 
docetaxel concentration, mean droplet size, and PI of 
the nanoemulsions. As shown in Supplementary Table I, 
reducing the total amount of surfactant from 240 to 60 μmole 
at a fixed Tween 80:Span 85 ratio decreased the loaded 
docetaxel concentration by 3.7-fold while increasing the 
particle size by 2.2-fold. These data indicate that the loaded 
docetaxel concentration was very dependent on the total 
surfactant amount, and 240 μmole of surfactant mixture per 
milliliter of emulsion dispersions was required to produce 
iodine-docetaxel emulsions with nanoscale size.
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Because the use of nanoparticles as a carrier for 
taxane drugs, including docetaxel, is often hampered by 
the time-dependent release/precipitation of the drug [16], 
the stability of iodine-docetaxel emulsions was tested 
by measuring time-dependent changes in mean particle 
size and concentration of loaded docetaxel. Docetaxel 
loaded in emulsions containing 65% Tween 80 tended to 
precipitate in a time-dependent manner during storage at 
4°C. Greater than 40% of loaded docetaxel was released/
precipitated from micelles after 2 weeks of storage (Figure 
1A). In contrast, nanoemulsions containing 87% Tween 
80 showed greatly improved stability; no significant 
loss of docetaxel loaded in nanoemulsions was observed 
after storage for up to 8 weeks at 4°C. With regard to the 
mean particle size, no significant change in the particle 
size was found during storage up to 12 weeks, regardless 
of formulation (Figure 1B). Collectively, these results 
suggest that nanoemulsions with an inner iodized oil core 
stabilized by an 87:13 mixture of Tween 80 and Span 85 
are a potential vehicle for stably carrying docetaxel.
The diameter and morphology of the emulsion 
obtained with the 87:13 mixture of Tween 80:Span 85 
were also determined by TEM. As demonstrated by 
the representative TEM image shown in Figure 1C, the 
majority of the particles in this emulsion are spherical and 
less than 100 nm in size, in agreement with the results 
obtained by the dynamic light scattering method.
CT lymphography for SLN imaging
In our previous study, we demonstrated that water-
soluble emulsions containing iodine can serve as an effective 
CT lymphography tracer [9]. Our newly-synthesized 
iodine-docetaxel emulsion was similar to the previous 
versions in design and synthesis protocol, but differed in 
composition. Therefore, we first intended to verify whether 
the iodine-docetaxel emulsion would reliably serve as a CT 
lymphography agent, by testing in both healthy rabbits and 
microscopic LN metastasis rabbit models.
The LN metastasis model was generated by 
passage of tumors from the popliteal LN of VX2 tumor-
implanted rabbits to additional heathy rabbits. Initially, 
the passage of VX2 tumors harvested from the popliteal 
LN was successful in no more than 50% of the rabbits, 
but the success rate gradually increased as we repeated 
passaging the tumors (data not shown). We believe that a 
tumor subpopulation with an enhanced tendency for nodal 
metastasis was selected for during passaging, causing 
the rate of popliteal LN metastasis to gradually increase. 
After several cycles of tumor passaging, we were able to 
establish a VX2 tumor line that showed enhanced nodal 
metastasis potential and usually achieved a popliteal LN 
metastasis rate of approximately 90% (data not shown) 
when incubated for 4 weeks after implantation. All 
subsequent experiments were performed using this VX2 
tumor line.
We performed CT lymphography in tumor-free 
healthy rabbits (n=3). CT images obtained 12 hours 
after subcutaneous injection of the iodine-docetaxel 
emulsion demonstrated focal contrast enhancement 
within the popliteal lymph node ipsilateral to the tumor 
(Figure 2A).
Next, we conducted SLN imaging in the rabbit 
microscopic LN metastasis model (n=6). Similar to 
the tumor-free healthy rabbits, CT lymphography was 
performed 12 hours after subcutaneous injection of the 
iodine-docetaxel emulsion, which also revealed focal 
intra-nodal enhancement by the uptake of emulsion 
(Figure 2B, 2C). A second session of CT lymphography 
was performed 7 days later and showed that the 
iodine-docetaxel emulsion washed away, as intranodal 
enhancement was no longer present (Figure 2D).
SLN CT volume measurement
The pre-treatment CT images obtained 10 days 
after VX2 tumor implantation were used for volumetry. 
The rabbits were alternatively allocated into the treatment 
group (n=17) or non-treatment (control) group (n=17) 
according to the size of the popliteal LN ipsilateral to the 
implanted tumor so that the two groups had matched LN 
size (mean ± standard deviation: treatment group, 0.424 
± 0.130 cm3 vs. non-treatment group, 0.447 ± 0.137 cm3; 
P=0.612). The size of the contralateral side popliteal 
LNs were also the same between the two groups upon 
allocation (mean ± standard deviation: treatment group, 
0.159 ± 0.146 cm3 vs. non-treatment group, 0.182 ± 0.102 
cm3; P=0.589) (Figure 3). Shortly after the pre-treatment 
CT was obtained, the treatment group rabbits received a 
peri-tumoral injection of the iodine-docetaxel emulsion.
Seven days after injection of the iodine-docetaxel 
emulsion in the treatment group (17 days after VX2 
tumor implantation), a post-treatment CT was performed. 
Volumetry based on the post-treatment CT revealed 
that the sizes of the ipsilateral LNs in the treatment 
group compared to the non-treatment group were not 
significantly different (mean ± standard deviation: 
treatment group, 0.900 ± 0.283 cm3 vs. non-treatment 
group, 0.812 ± 0.193 cm3; P=0.296). Meanwhile, the sizes 
of the ipsilateral popliteal LNs significantly increased in 
both the treatment and non-treatment groups when the size 
measured on the post-treatment CT was compared with 
that of the pre-treatment CT within each group (paired 
t-test, P<0.001 in both groups) (Figure 3). However, the 
volume of the contralateral popliteal LN measured on the 
post-treatment CT did not differ between the two groups 
(mean ± standard deviation: treatment group, 0.176 ± 
0.217 vs. non-treatment group, 0.176 ± 0.090; P=1.000), 
nor did it differ when comparing the pre-treatment CT and 
post-treatment CT of either group (paired t-test, within 
treatment group P=0.332; within non-treatment group 
P=0.332) (Figure 3).
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Figure 1: Emulsion stability assessed by changes in (A) loaded docetaxel concentration and (B) mean particle size of emulsions. The 
loaded docetaxel concentration of emulsions stored at 4°C was determined by HPLC analysis and change in droplet size was measured 
using a dynamic light scattering method. Data are presented as mean ± S.D. (n=3). (C) Representative TEM image of an iodine-docetaxel 
emulsion obtained with an 87:13 mixture of Tween 80:Span 85.
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Treatment response measurement
Both the non-treatment group (Figure 4) and 
treatment group rabbits (Figure 5) had an increased 
volume of the ipsilateral popliteal LNs compared 
with that of the contralateral popliteal LNs (Figure 3, 
4C, 5C). Microscopic examination of the dissected 
ipsilateral popliteal LNs detected LN tumor metastasis 
more frequently in the non-treatment group than the 
treatment group (Figure 4D, 4E, 5D, 5E, 6). The ratio 
of positive LN metastasis was significantly lower 
(P=0.038) in the treatment group, as 70.6% (n=12/17) 
of the non-treatment group rabbits developed positive 
LN metastasis, compared with 29.4% (n=5/17) in the 
treatment group (Figure 6). The volumetry based on 
the post-treatment CT did not show a statistically 
significant difference according to the presence or 
absence of metastasis (mean ± standard deviation: LN 
Figure 2: CT lymphography after subcutaneous injection of an iodine-docetaxel emulsion for sentinel lymph node 
(SLN) imaging in rabbit models. Lower extremity CT of a (A) healthy control rabbit performed 12 hours after iodine-docetaxel 
emulsion injection. Multiphasic CT lymphography images of a VX2 tumor-implanted rabbit model obtained (B) before, (C) 12 hours 
after, and (D) 7 days after iodine-docetaxel emulsion injection. Focal intra-nodal contrast enhancement (arrow) within the popliteal LN 
(arrowheads) caused by the subcutaneously injected iodine-docetaxel emulsion (small arrows) was observed. Magnified images of the 
ipsilateral popliteal images showing focal uptake of iodine-docetaxel emulsion (Inset) are provided.
Figure 3: CT volumetry of the popliteal LNs of VX2-implanted rabbits performed before (pre-treatment CT) and 7 
days after (post-treatment CT) injection. The rabbits were divided into the treatment group (n=17), which received subcutaneous 
injection of the iodine-docetaxel emulsion, or the non-treatment (control) group (n=17).
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Figure 4: A non-treatment (control) group VX2-implanted rabbit. Images obtained during (A) the pre-treatment CT session (10 
days after tumor implantation) and (B) the post-treatment CT session (17 days after tumor implantation). The popliteal LN (arrowhead) 
ipsilateral to the implanted tumor increased in size from 0.4 to 0.9 cm3. (C) Gross image of the dissected popliteal LNs at the ipsilateral 
(arrow) and contralateral (arrowheads) side of the tumor. Microscopic images of (D) hematoxylin and eosin staining (40×) and (E) anti-
cytokeratin (AE1+AE3 antibody) immunohistochemistry staining (40×) of the ipsilateral popliteal LN demonstrated tumor metastasis 
(arrows).
Figure 5: A treatment group VX2-implanted rabbit. Images obtained during (A) the pre-treatment CT (10 days after tumor 
implantation) and (B) the post-treatment CT (17 days after tumor implantation, 7 days after iodine-docetaxel emulsion injection). 
The popliteal LN (arrowheads) ipsilateral to the implanted tumor increased in size from 0.3 to 0.6 cm3, and focal intra-nodal contrast 
enhancement (arrow) by uptake of the injected iodine-docetaxel emulsion (small arrows) was observed. Magnified image of the ipsilateral 
popliteal images showing focal uptake of iodine-docetaxel emulsion (Inset) is provided. (C) Gross image of the dissected popliteal LNs at 
the ipsilateral (arrow) and contralateral (arrowhead) side of the tumor. Microscopic images of (D) hematoxylin and eosin staining (40×) 
and (E) anti-cytokeratin (AE1+AE3 antibody) immunohistochemistry staining (40×) of the ipsilateral popliteal LN revealed no evidence 
of tumor metastasis.
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positive for metastasis, 0.882 ± 0.260 cm3 vs. negative 
for metastasis, 0.829 ± 0.229 cm3; P=0.533).
DISCUSSION
In the current study, we developed an iodine-
docetaxel emulsion and demonstrated that it can be 
applied as a SLN lymphography tracer and a vehicle 
that selectively delivers a chemotherapy agent into the 
tumor draining lymphatic system. We showed that peri-
tumoral injection of our iodine-docetaxel emulsion can 
significantly reduce the rate of LN metastasis in a LN 
micro-metastasis model (VX2 tumor-implanted rabbits).
In our previous study, we developed a water-
soluble emulsion containing iodized oil and fluorescent 
dye and demonstrated that it can be used to perform 
SLN hybrid imaging with both CT and optical devices 
[9]. Based on such experience, we learned that a variety 
of emulsions can be produced to generate tracers with 
additional capabilities. We also previously showed that 
water-soluble emulsions with optimal particle size will 
accumulate within the draining LNs, instead of being 
rapidly washed away like the classical vital dye tracers 
used for SLN detection [9]. We hypothesized that if 
the water-soluble emulsion is mixed with a cytotoxic 
agent, then the tumor draining lymphatic system would 
become selectively exposed to the cytotoxic agent in high 
concentration as the tracer accumulates. Consequently, 
a fortified chemotherapy regimen specifically targeting 
the compartment of the draining lymphatic system could 
be established. To fulfill this scenario, we integrated the 
chemotherapy agent docetaxel into the scaffold of our 
previous version of emulsion designed as an SLN tracer. 
We believe that our approach can not only enable SLN 
detection, but also actively eradicate microscopic LN 
metastasis.
The capability to simultaneously perform SLN 
imaging and locoregional chemotherapy of the draining 
lymphatic system has several clinical implications and 
advantages. Most importantly, under usual clinical 
settings a surgical biopsy may not be feasible even if SLN 
imaging is practically possible. Nowadays, minimally 
invasive procedures, such as endoscopic resection or 
trans-anal operation, are increasingly performed for 
the treatment of early gastric cancer or early colorectal 
cancer, but the prediction and treatment of potential nodal 
Figure 6: The rate of popliteal LN metastasis in VX2 tumor-implanted rabbits as detected by microscopic examination 
17 days after tumor implantation (or 7 days after iodine-docetaxel emulsion injection in the treatment group). The rate 
of popliteal LN metastasis was 29.4% (n=5/17) in the treatment group versus 70.6% (n=12/17) in the non-treatment group, indicating that 
LN metastasis occurred less frequently in the treatment group (*P=0.038).
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metastasis remains a challenge because LN biopsy is not 
possible during these procedures [17, 18]. However, peri-
tumoral injection of SLN tracers can be easily performed 
during these minimally invasive procedures along with a 
subsequent CT lymphography to perform SLN imaging. 
The treatment effect of our iodine-docetaxel emulsion can 
reduce the risk of potential microscopic LN metastasis, 
which we believe is a significant advantage because such 
minimally invasive endoscopic resection procedures stand 
on the assumption that tumor cells have not entered the 
draining lymphatic system, despite the fact that the LNs 
remain unexamined.
In early gastric cancer, the risk of LN metastasis 
has been reported to range between 1% to 3% if the 
tumor is confined to the mucosa, and 11% to 20% if 
the tumor invades the submucosa [18, 19]. Currently, 
endoscopic resection is considered as standard treatment 
in carefully selected patients who meet the absolute 
indication (differentiated type adenocarcinoma without 
ulcer and the depth of invasion is clinically diagnosed 
as T1a and the diameter is ≤2cm) because the risk of 
positive LN metastasis is low in these patients [20]. 
Meanwhile, ongoing debate exists on whether or not 
endoscopic resection can be safely performed in early 
gastric cancer beyond the absolute indication due to 
the risk of regional LN metastasis [21–23]. We believe 
that our iodine-docetaxel emulsion, which can be easily 
injected around the tumor during endoscopic resection, 
can be applied to control any undetected microscopic 
LN metastasis and therefore contribute to expand the 
application of such minimally invasive treatments. 
Moreover, this approach also can detect the SLN (or 
SLN basin) by CT, which can be used if a SLN biopsy is 
later decided to be necessary.
Our iodine-docetaxel emulsion can also improve 
safety in patients who decide not to undergo curative 
resection based on a negative SLN biopsy. Although 
SLN biopsy is an established method in several kinds of 
malignancies, the risk of a false negative report cannot 
be eliminated for several reasons. Firstly, during daily 
practice, a whole-mount examination of the retrieved 
SLN cannot be performed, and thus under-sampling is 
inevitable. Secondly, the current SLN detection methods 
have a risk of technical failure. Water-soluble dyes, 
including vital dyes, not only rapidly wash away and 
therefore allow only limited time for assessment, but 
may become obscured when covered by dense fat tissue. 
Radioactive colloid tracers have poor spatial resolution 
and are known to exhibit poor sensitivity when the LN 
is near the injection site because of high background 
scattering (shine-through effect) [24–26].
According to clinical reports, the majority of 
metastatic LNs discovered in colorectal and gastric cancer 
patients were not significantly enlarged [27–29], which 
is why the prediction of nodal metastasis is extremely 
challenging. The presence of an overt metastatic 
deposit (and consequently an unequivocally enlarged 
LN) would frequently occlude the lymphatic channels, 
causing SLN imaging based on tracer injection to be 
inaccurate. However, we believe that larger LNs would 
likely carry metastatic deposits with a tumor burden 
at a level that is unreasonable to attempt treatment 
based on a non-surgical method, including our iodine-
docetaxel emulsion injection method. Therefore, we 
excluded rabbits with large popliteal LNs (>1 cm3) at 
pre-treatment CT.
In the current study, the size of the ipsilateral LNs 
measured on post-treatment CT increased during the 7 day 
incubation period in both the treatment group and non-
treatment group (P<0.001 in both) when compared with 
the pre-treatment CT. However, in spite of the difference 
in the nodal metastasis rate between the treatment group 
and non-treatment group, the size of the LNs of the two 
groups was not significantly different (mean ± standard 
deviation: treatment group, 0.900 ± 0.283 cm3 vs. non-
treatment group 0.812 ± 0.193 cm3; P=0.296). This 
implies that although treatment with the iodine-docetaxel 
emulsion might lower the rate of nodal metastasis, the 
treatment response is not reflected by a decrease in size of 
a particular LN, which would make it difficult to predict 
eradication of potential metastasis based on size alone. We 
believe that the increased size of non-metastatic LNs is 
probably associated with the state of reactive hyperplasia 
[29, 30].
It has been reported that docetaxel can reach much 
higher concentrations when packed in lipid emulsion 
form [31]. Docetaxel is a lipophilic agent, and the lipid 
emulsion can serve as a drug carrier that allows for the 
slow release of docetaxel [31]. A previous study showed 
that lipophilic drugs formulated in lipid emulsions can 
reach higher plasma concentrations than those in solution 
after intravenous injection [32]. Thus, by synthesizing our 
tracer in lipid emulsion form, we attempted to achieve 
similar pharmacokinetic benefits and speculated that the 
concentration of docetaxel within the draining LNs could 
be maximized.
Our formulation study, which was performed 
to optimize the composition of surfactants in order to 
maximize the loaded docetaxel concentration in the 
emulsion tracer, demonstrated that 240 μmole/ml of an 
87:13 mixture of Tween 80:Span 85 enabled docetaxel 
loading at a 4% drug-to-surfactant weight ratio, a ratio 
comparable to that in Taxotere®, where 40 mg docetaxel 
is solubilized in an ethanol-surfactant mixture containing 
1075 mg Tween 80 (3.6%). The mean size of optimized 
emulsions was less than 100 nm, the upper size limit 
for colloidal particles to enter the lymphatic capillaries 
quickly and accumulate in regional LNs after subcutaneous 
administration [33]. Moreover, they exhibited very high 
stability in terms of particle size and loaded docetaxel 
content during storage. Since docetaxel was retained as 
loaded in nanoemulsions but not in micelles obtained 
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with the same Tween 80:Span 85 surfactant ratio, it 
seems likely that the presence of iodized oil contributed 
to inhibiting the docetaxel precipitation. We believe that 
the docetaxel was likely solubilized mainly in the iodized 
oil core together with surfactants; thus, the presence of 
iodized oil not only enables CT imaging but also stabilizes 
docetaxel-loaded emulsions.
We acknowledge that our study had a few 
limitations. Firstly, our study was based on a microscopic 
LN metastasis animal model in which the presence or 
absence of LN metastasis was unknown at the time of 
iodine-docetaxel emulsion injection. As a result, we 
were not able to measure the direct treatment effect on 
LN metastasis. To compensate for this limitation, we 
established a balanced control group with matched 
popliteal LN sizes, which served as a non-treatment 
(control) group for comparison. Secondly, to ensure the 
clarity of this proof-of-concept study, we performed 
experiments while using the popliteal LN as the SLN 
for the VX2 tumor implanted in the lower extremity. 
However, the lymphatic vessels of this area are very 
simple, and therefore we do not believe that our iodine-
docetaxel emulsion has been sufficiently validated as a 
SLN tracer. We intend to pursue further validation in a 
more clinically relevant tumor model with more complex 
lymphatic structures.
In conclusion, we have developed an iodine-
docetaxel emulsion and applied it to simultaneously 
accomplish SLN detection based on CT lymphography 
and eradication of potential LN metastasis by selectively 
delivering chemotherapy into the draining lymphatic 
system.
MATERIALS AND METHODS
This study was approved by the Experimental 
Animal Ethical Committee of Yonsei University College 
of Medicine (approval number: 2013-0248).
Preparation of nanoemulsions
Sorbitan trioleate (Span 85) and 
polyoxyethylenesorbitan monooleate (Tween 80) were 
purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). 
Docetaxel was purchased from LC laboratories (Woburn, 
MA, USA). Lipiodol, an FDA-approved iodized oil, was 
purchased from Guerbet (Aulnay-Sous-Bois, France). All 
other materials were of reagent grade and used without 
further purification.
Oil-in-water emulsions were prepared using a 
homogenization method as previously described [34]. 
Briefly, 7 mg of docetaxel and 300 μl of Lipiodol were 
dissolved in ethanol together with varying amounts of 
surfactant mixture (Tween 80 and Span 85). Ethanol was 
removed under reduced pressure using a rotary evaporator 
until a pre-emulsion concentrate was obtained. We then 
added 0.7 ml of saline dropwise to the pre-emulsion 
concentrate while vortexing, followed by sonication in a 
bath sonicator at 37°C for 30 min. The obtained emulsions 
were placed in an ice bath, then homogenized at 11,000 
rpm using a homogenizer (IKA-Wereke, Stufen, Germany) 
in four intervals (durations: 10, 5, 5, and 5 min), to obtain 
a homogeneous nanoemulsion. Unloaded docetaxel was 
removed from the emulsion dispersion by filtering through 
an 0.8-μm syringe membrane filter. The filtered emulsions 
were stored at 4°C until use.
Physicochemical characterization of emulsions
The mean particle size and PI of the nanoemulsions 
were measured by dynamic light scattering using a fiber-
optic particle analyzer (FPAR-1000, Otsuka Electronics, 
Japan). Prior to measurement, the emulsion dispersions 
were appropriately diluted with filtered saline. The PI was 
obtained as a measure of the uniformity of the particle size 
distribution in colloidal dispersions [35].
The concentration of docetaxel loaded in the 
emulsions was determined by reversed-phase HPLC 
analysis [35]. In brief, 50 μl of each filtered emulsion 
was rapidly frozen, dried in a freeze dryer (FDU-1200, 
EYELA, Japan), then redissolved in methanol. Twenty 
microliters of sample were injected into the Nanospace SI-
2HPLC system (Shiseido, Japan) equipped with a mobile 
phase delivery pump (SP 3201) and UV-vis detector 
(SP 3002). A mixture of acetonitrile and distilled water 
(65:35, v/v) was used as a mobile phase at a flow rate 
of 1 ml/min. A reversed-phase Capcell pak C18 column 
(UG120, Shiseido, Japan) was used at 35°C. The detector 
wavelength was set at 230 nm.
The diameter and morphology of nanoemulsions 
were also determined by transmission electron microscopy 
(TEM; Tecnai G2 Spirit, FEI) at an accelerator voltage of 
120 kV. For observation, 5 μl of emulsion were applied 
to carbon-coated grids that had been glow discharged for 
3 min in air and immediately (within ~5 sec) negatively 
stained using 1% uranyl acetate.
The stability of nanoemulsions was evaluated by 
monitoring the changes in mean particle size and the 
docetaxel content remaining loaded in emulsions during 
storage at 4°C.
Animal model of popliteal LN metastasis
Male New Zealand white rabbits weighing from 
3 to 3.5 kg each were used. Anesthesia was induced by 
intramuscular injection of 5 mg of a 1:1 combination 
mixture of zolazepam (Zoletil; Vibrac Laboratories, 
Carros, France) and xylazine hydrochloride (Rompun; 
Bayer, Seoul, Korea) per kilogram body weight.
VX2 tumors exhibiting enhanced tendency to 
metastasize to the LN were selected through multiple 
rounds of passaging. Rabbits implanted with a VX2 tumor 
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in the lower extremity muscle were incubated for 4 to 5 
weeks to allow popliteal LN metastasis to occur. Under 
anesthesia, the popliteal LN ipsilateral to the implanted 
tumor (where it was assumed, but not confirmed, that nodal 
metastasis had developed) was harvested and minced into 
approximately 1-mm3 pieces. This fresh tissue suspension 
was implanted into another rabbit within the muscles at the 
outer side of the distal portion of right tibia at a total volume 
of 0.1 ml. The rabbit was incubated for 4 to 5 weeks until 
tumor passage to the next rabbit was performed.
SLN imaging based on CT lymphography
First, we intended to test whether our iodine-
docetaxel emulsion could serve as a SLN tracer. Under 
anesthesia, we subcutaneously injected the iodine-
docetaxel emulsion at the right lower extremity in healthy 
control rabbits (n=3) and VX2 tumor-implanted rabbits 
(n=6, incubated for 10 days). Each rabbit received three 
0.7-ml injections for 2.1 ml in total, either within a 
narrow area (healthy rabbits) or at a peri-tumoral location 
(tumor-implanted rabbits). CT images were obtained 
before and 12 hours after subcutaneous injection of the 
iodine-docetaxel emulsion. The VX2 tumor-implanted 
rabbits underwent a follow-up CT scan 7 days after this 
procedure.
CT lymphography was performed with a 
commercial 64-channel multidetector scanner (Discovery 
CT750 HD; GE Healthcare, Milwaukee, Wis) with the 
following parameters: 120 kV, 250 mA, 0.625-mm beam 
collimation, and 1.25-mm axial reconstruction thickness. 
The field of view was adjusted to include the entire 
abdomen and lower extremities.
Treatment response measurement
Thirty-six New Zealand white rabbits implanted 
with a VX2 tumor in the muscle of right side lower 
limb and incubated for 10 days served as a model of 
microscopic LN metastasis. A CT scan was performed 
twice, just before peri-tumoral injection of the iodine-
docetaxel emulsion (pre-treatment CT) and 7 days after 
injection (post-treatment CT). Volumetry of popliteal LNs 
was also conducted twice in each rabbit based on the pre-
treatment CT and post-treatment CT.
For volume measurement of the popliteal LNs, the 
CT axial images were archived in Digital Imaging and 
Communications in Medicine (DICOM) format and stored 
on a General Electric Advantage v4 work station (GE 
Healthcare, Waukesha, WI). The region of interest (ROI) 
was drawn along the margin of the popliteal LN on each 
slice, and total mass was calculated by adding ROI areas 
in consecutive images. The volumes of popliteal LNs were 
measured on both the ipsilateral and contralateral side to 
the implanted tumor.
In humans, it is known that metastatic LNs tend 
to increase in size [36, 37], and we speculated that large 
LNs may represent LNs carrying gross metastasis deposits 
rather than microscopic metastases. As we tried to simulate 
a microscopic nodal metastasis model, we intended to 
exclude rabbits with LNs carrying overt metastasis at the 
time of SLN assessment. Therefore, we defined 1 cm3 as 
a volume threshold and excluded rabbits (n=2) in which 
the volume of their ipsilateral popliteal LNs exceeded 1 
cm3 on pre-treatment CT. The remaining rabbits (n=34) 
were alternatively allocated into the treatment group 
(n=17) or non-treatment (control) group (n=17) according 
to the volume of the ipsilateral popliteal LN measured on 
pre-treatment CT. Shortly after the pre-treatment CT scan 
was obtained and volumetry was performed, the treatment 
group rabbits received peri-tumoral subcutaneous 
injections (three 0.7 ml injections, 2.1 ml in total) around 
the tumor nodule. Seven days later (17 days after the 
tumor was implanted), a post-treatment CT scan was 
conducted. Afterwards, all rabbits were euthanized with 
saturated potassium chloride and the bilateral popliteal 
LNs were sampled.
Analysis of the dissected popliteal LNs
The sampled popliteal LNs were fixed in 10% 
buffered formalin overnight, then embedded in paraffin and 
sectioned at 5-mm intervals. We performed hematoxylin 
and eosin staining and immunohistochemical staining 
using anti-cytokeratin monoclonal antibodies (anti-
cytokeratin AE1+AE3 antibody, Abcam Inc., Cambridge, 
MA). The slides were reviewed by a pathologist (K.S.K.) 
with 5 years of experience in experimental animal 
histopathology to determine the presence or absence of 
metastatic tumor cells.
Statistical analysis
Statistical analysis was performed using standard 
software (SPSS v20.0 for Windows, SPSS Inc., Chicago, 
IL, USA). Student’s t-test was used to compare the volume 
of popliteal LNs between the treatment group and non-
treatment group. Paired t-test analysis was applied to 
compare the volumes of a popliteal LN measured on 
the pre-treatment and post-treatment CT scans. Fisher’s 
exact test was performed to compare the rate of tumor LN 
metastasis between the treatment group and non-treatment 
group. Statistical significance was defined as P<0.05.
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